Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 13882
Country/Region: Kenya
Year: 2017
Main Partner: Children of God Relief Fund
Main Partner Program: NA
Organizational Type: FBO
Funding Agency: USAID
Total Funding: $1,443,097 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $785,169
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $0
Testing: HIV Testing and Counseling (HVCT) $23,719
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,467
Treatment: Adult Treatment (HTXS) $150,433
Treatment: Pediatric Treatment (PDTX) $482,309
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2018 967
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2018 220
GEND_GBV <10, Male, Physical and/or Emotional Violence 2018 1,267
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2018 130
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2018 1,541
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2018 367
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2018 1,084
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2018 132
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2018 1,248
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2018 296
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2018 951
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2018 112
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2018 271
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2018 57
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2018 253
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2018 23
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 201
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 7,588
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 1,337
GEND_GBV Number of people receiving post-GBV care 2018 8,925
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 7,371
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2018 418
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2018 2,180
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2018 447
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2018 460
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2018 413
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2018 329
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2018 647
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2018 276
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Female, Negative 2018 1,060
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Male, Negative 2018 618
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2018 63
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2018 83
HTS_TST Sum of Test Result disaggregates 2018 377
HTS_TST_POS By Test Result: Positive 2018 377
HTS_TST_POS Service Delivery Point (Facility) VCT: <1, Positive 2018 80
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2018 117
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2018 29
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2018 25
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2018 17
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2018 20
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2018 19
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2018 4
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Female, Positive 2018 34
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Male, Positive 2018 12
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2018 16
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2018 4
OVC_SERV Age/Sex: <1 2018 110
OVC_SERV Age/Sex: 1-9 2018 4,034
OVC_SERV Age/Sex: 10-14 Female 2018 3,529
OVC_SERV Age/Sex: 10-14 Male 2018 1,839
OVC_SERV Age/Sex: 15-17 Female 2018 2,860
OVC_SERV Age/Sex: 15-17 Male 2018 1,585
OVC_SERV By: Age/sex: 18-24 Female 2018 613
OVC_SERV By: Age/sex: Male 18-24 2018 417
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2018 14,987
OVC_SERV Program Completion: Active 2018 14,987
OVC_SERV Sum of Age/Sex disaggregates 2018 9,813
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 14
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 2
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 16
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 32
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 32
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 14
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 2
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 16
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 2
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 14
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 3
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 16
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 35
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 35
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 2
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 14
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 3
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 16
TX_CURR Age/Sex: <1 2018 12
TX_CURR Age/Sex: <1-9 2018 812
TX_CURR Age/Sex: 10-14 Female 2018 624
TX_CURR Age/Sex: 10-14 Male 2018 594
TX_CURR Age/Sex: 15-19 Female 2018 539
TX_CURR Age/Sex: 15-19 Male 2018 480
TX_CURR Age/Sex: 20-24 Female 2018 132
TX_CURR Age/Sex: 20-24 Male 2018 116
TX_CURR Age/Sex: 25-49 Female 2018 14
TX_CURR Age/Sex: 25-49 Male 2018 9
TX_CURR Age/Sex: 50+ Female 2018 9
TX_CURR Age/Sex: 50+ Male 2018 6
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 3,347
TX_CURR Sum of age/sex disaggregates 2018 1,019
TX_NEW By Age/Sex: <1 2018 4
TX_NEW By Age/Sex: 1-9 2018 42
TX_NEW By Age/Sex: 10-14 Female 2018 43
TX_NEW By Age/Sex: 10-14 Male 2018 40
TX_NEW By Age/Sex: 15-19 Female 2018 24
TX_NEW By Age/Sex: 15-19 Male 2018 14
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 167
TX_NEW Sum of Age/Sex disaggregates 2018 121
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 3,347
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 2,683
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 840
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 797
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 558
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 488
TX_PVLS Numerator: Indication: Routine 2018 2,683
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 1,047
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 995
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 694
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 611
TX_PVLS_den Denominator: Indication: Routine 2018 3,347
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 59
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 55
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 23
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 13
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 150
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 167
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 67
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 62
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 24
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 14
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 3,347
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 12
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 1
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 5
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 6
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 1,047
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 995
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 694
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 611
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 534
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 33
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 101
TX_TB_den Denominator: By Screen Result: Negative 2018 2,680
TX_TB_den Denominator: By Screen Result: Positive 2018 667
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 634